Long-term follow-up after BEAM-101 treatment
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study is for people who have already received BEAM-101 in a previous study. It simply follows them over time to track their health and any long-term effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have received BEAM-101 as part of the earlier study (BTX-AUT-001).
- You must be finishing up that earlier study and ready for your final visit.
- You must be willing to sign a consent form to participate in this long-term follow-up study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is a long-term follow-up for people who already received gene therapy for sickle cell disease in a specific sponsor’s clinical trial. It helps researchers watch for long-term safety and outcomes over time.
This study follows people for a long time after they received CTX001 in an earlier (parent) study. It helps researchers learn about long-term safety and outcomes of the treatment.
This long-term follow-up study monitors people with sickle cell disease or transfusion-dependent beta-thalassemia who have already received the gene-editing therapy EDIT-301. It helps researchers understand how safe and effective the treatment is over time.
This trial tests a new treatment called BRL-101 for people with severe sickle cell disease. The treatment uses your own stem cells, which are modified in the lab and then given back to you. It aims to reduce pain crises and improve your quality of life.
This study follows up on people who have already received the CS-101 infusion in a previous trial. It aims to check how participants are doing over time. There are no restrictions to join if you already received CS-101.
This study follows patients who have already been treated with BRL-101 for transfusion-dependent beta-thalassemia. Its goal is to track long-term outcomes and safety.
Hear when a new Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.